

# Peter J Hoskin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1592381/publications.pdf>

Version: 2024-02-01

302  
papers

26,498  
citations

9786

73  
h-index

6996

154  
g-index

343  
all docs

343  
docs citations

343  
times ranked

20792  
citing authors

#	ARTICLE	IF	CITATIONS
1	Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer. <i>New England Journal of Medicine</i> , 2013, 369, 213-223.	27.0	2,723
2	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.	27.0	1,315
3	The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial. <i>Lancet, The</i> , 2008, 371, 1098-1107.	13.7	1,030
4	Palliative Radiotherapy for Bone Metastases: An ASTRO Evidence-Based Guideline. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 965-976.	0.8	765
5	Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting. <i>European Urology</i> , 2011, 59, 477-494.	1.9	642
6	Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma. <i>New England Journal of Medicine</i> , 2015, 372, 1598-1607.	27.0	619
7	Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study. <i>Radiotherapy and Oncology</i> , 2016, 120, 428-433.	0.6	527
8	Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. <i>Annals of Oncology</i> , 2018, 29, iv166-iv191.	1.2	461
9	Randomised trial of external beam radiotherapy alone or combined with high-dose-rate brachytherapy boost for localised prostate cancer. <i>Radiotherapy and Oncology</i> , 2012, 103, 217-222.	0.6	445
10	Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. <i>Lancet Oncology, The</i> , 2014, 15, 738-746.	10.7	433
11	Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial. <i>Lancet Oncology, The</i> , 2018, 19, 295-309.	10.7	426
12	The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. <i>Clinical and Translational Radiation Oncology</i> , 2018, 9, 48-60.	1.7	415
13	Myocardial Infarction Mortality Risk After Treatment for Hodgkin Disease: A Collaborative British Cohort Study. <i>Journal of the National Cancer Institute</i> , 2007, 99, 206-214.	6.3	411
14	Non-Small Cell Lung Cancer: Histopathologic Correlates for Texture Parameters at CT. <i>Radiology</i> , 2013, 266, 326-336.	7.3	384
15	Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, double-blind, phase 3 ALSYMPCA trial. <i>Lancet Oncology, The</i> , 2014, 15, 1397-1406.	10.7	351
16	Survival with Newly Diagnosed Metastatic Prostate Cancer in the Docetaxel Era: Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). <i>European Urology</i> , 2015, 67, 1028-1038.	1.9	340
17	Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. <i>Urology</i> , 2004, 63, 940-945.	1.0	326
18	Evaluation of Five Radiation Schedules and Prognostic Factors for Metastatic Spinal Cord Compression. <i>Journal of Clinical Oncology</i> , 2005, 23, 3366-3375.	1.6	323

#	ARTICLE	IF	CITATIONS
19	Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial. <i>Radiotherapy and Oncology</i> , 2011, 100, 86-92.	0.6	309
20	International consensus on palliative radiotherapy endpoints for future clinical trials in bone metastases. <i>Radiotherapy and Oncology</i> , 2002, 64, 275-280.	0.6	300
21	Prognostic Factors for Local Control and Survival After Radiotherapy of Metastatic Spinal Cord Compression. <i>Journal of Clinical Oncology</i> , 2006, 24, 3388-3393.	1.6	292
22	Update of the International Consensus on Palliative Radiotherapy Endpoints for Future Clinical Trials in Bone Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1730-1737.	0.8	283
23	MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. <i>Lancet Oncology</i> , The, 2021, 22, 538-547.	10.7	268
24	Radiotherapy With Concurrent Carbogen and Nicotinamide in Bladder Carcinoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 4912-4918.	1.6	264
25	Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. <i>Radiotherapy and Oncology</i> , 2007, 83, 3-10.	0.6	253
26	Effect of tumor dose, volume and overall treatment time on local control after radiochemotherapy including MRI guided brachytherapy of locally advanced cervical cancer. <i>Radiotherapy and Oncology</i> , 2016, 120, 441-446.	0.6	252
27	Single versus multiple fractions of repeat radiation for painful bone metastases: a randomised, controlled, non-inferiority trial. <i>Lancet Oncology</i> , The, 2014, 15, 164-171.	10.7	239
28	GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update. <i>Radiotherapy and Oncology</i> , 2013, 107, 325-332.	0.6	236
29	Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. <i>Radiotherapy and Oncology</i> , 2016, 120, 434-440.	0.6	236
30	Randomized trial of 8Gy in 1 versus 20Gy in 5 fractions of radiotherapy for neuropathic pain due to bone metastases (Trans-Tasman Radiation Oncology Group, TROG 96.05). <i>Radiotherapy and Oncology</i> , 2005, 75, 54-63.	0.6	233
31	A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 4879-4888.	7.0	214
32	High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. <i>Radiotherapy and Oncology</i> , 2007, 84, 114-120.	0.6	199
33	Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. <i>Radiotherapy and Oncology</i> , 2016, 120, 412-419.	0.6	198
34	ESMO Guidelines consensus conference on malignant lymphoma 2011 part 1: diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and chronic lymphocytic leukemia (CLL). <i>Annals of Oncology</i> , 2013, 24, 561-576.	1.2	193
35	4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): a randomised phase 3 non-inferiority trial. <i>Lancet Oncology</i> , The, 2014, 15, 457-463.	10.7	191
36	BOLD MRI of human tumor oxygenation during carbogen breathing. <i>Journal of Magnetic Resonance Imaging</i> , 2001, 14, 156-163.	3.4	175

#	ARTICLE	IF	CITATIONS
37	Second Cancer Risk After Chemotherapy for Hodgkin's Lymphoma: A Collaborative British Cohort Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4096-4104.	1.6	175
38	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	13.7	173
39	Hypoxia in Prostate Cancer: Correlation of BOLD-MRI With Pimonidazole Immunohistochemistry—Initial Observations. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1065-1071.	0.8	169
40	Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort Study. <i>Journal of Clinical Oncology</i> , 2006, 24, 1568-1574.	1.6	166
41	Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. <i>Journal of Clinical Oncology</i> , 2009, 27, 5390-5396.	1.6	164
42	ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 49-61.	0.6	157
43	A Randomized, Double-Blind, Dose-Finding, Multicenter, Phase 2 Study of Radium Chloride (Ra 223) in Patients with Bone Metastases and Castration-Resistant Prostate Cancer. <i>European Urology</i> , 2013, 63, 189-197.	1.9	154
44	Dose—effect relationship and risk factors for vaginal stenosis after definitive radio(chemo)therapy with image-guided brachytherapy for locally advanced cervical cancer in the EMBRACE study. <i>Radiotherapy and Oncology</i> , 2016, 118, 160-166.	0.6	153
45	Breast Cancer Risk After Supradiaphragmatic Radiotherapy for Hodgkin's Lymphoma in England and Wales: A National Cohort Study. <i>Journal of Clinical Oncology</i> , 2012, 30, 2745-2752.	1.6	142
46	Lung Cancer Perfusion at Multi-Detector Row CT: Reproducibility of Whole Tumor Quantitative Measurements. <i>Radiology</i> , 2006, 239, 547-553.	7.3	132
47	Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. <i>EBioMedicine</i> , 2018, 31, 182-189.	6.1	132
48	EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort. <i>European Urology</i> , 2020, 77, 223-250.	1.9	132
49	The response of human tumors to carbogen breathing, monitored by gradient-recalled echo magnetic resonance imaging. <i>International Journal of Radiation Oncology Biology Physics</i> , 1997, 39, 697-701.	0.8	128
50	High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. <i>Radiotherapy and Oncology</i> , 2003, 68, 285-288.	0.6	124
51	Definitive Stereotactic Body Radiotherapy (SBRT) for Extracranial Oligometastases. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017, 40, 418-422.	1.3	124
52	Second primary cancers after radiation for prostate cancer: A systematic review of the clinical data and impact of treatment technique. <i>Radiotherapy and Oncology</i> , 2014, 110, 213-228.	0.6	121
53	Scoring systems used for the interpretation and reporting of multiparametric MRI for prostate cancer detection, localization, and characterization: could standardization lead to improved utilization of imaging within the diagnostic pathway?. <i>Journal of Magnetic Resonance Imaging</i> , 2013, 37, 48-58.	3.4	119
54	Use of Macrophages to Target Therapeutic Adenovirus to Human Prostate Tumors. <i>Cancer Research</i> , 2011, 71, 1805-1815.	0.9	111

#	ARTICLE	IF	CITATIONS
55	The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with Bone Metastases: The EORTC QLQ-BM22. <i>European Journal of Cancer</i> , 2009, 45, 1146-1152.	2.8	108
56	A Gene Signature for Selecting Benefit from Hypoxia Modification of Radiotherapy for High-Risk Bladder Cancer Patients. <i>Clinical Cancer Research</i> , 2017, 23, 4761-4768.	7.0	107
57	The evolution of brachytherapy for prostate cancer. <i>Nature Reviews Urology</i> , 2017, 14, 415-439.	3.8	106
58	Effect of nitric-oxide synthesis on tumour blood volume and vascular activity: a phase I study. <i>Lancet Oncology</i> , 2007, 8, 111-118.	10.7	105
59	High-Dose-Rate Brachytherapy Alone for Localized Prostate Cancer in Patients at Moderate or High Risk of Biochemical Recurrence. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, 1376-1384.	0.8	105
60	Magnetic resonance-guided radiation therapy: A review. <i>Journal of Medical Imaging and Radiation Oncology</i> , 2020, 64, 163-177.	1.8	104
61	Review of intraoperative imaging and planning techniques in permanent seed prostate brachytherapy. <i>Radiotherapy and Oncology</i> , 2010, 94, 12-23.	0.6	102
62	Cancer Pain: Part 1: Pathophysiology; Oncological, Pharmacological, and Psychological Treatments: A Perspective from the British Pain Society Endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners. <i>Pain Medicine</i> , 2010, 11, 742-764.	1.9	100
63	Retreatment with radiotherapy for painful bone metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 1994, 29, 1011-1014.	0.8	98
64	Metastatic spinal cord compression: radiotherapy outcome and dose fractionation. <i>Radiotherapy and Oncology</i> , 2003, 68, 175-180.	0.6	97
65	Cancer induced bone pain. <i>BMJ</i> , 2015, 350, h315-h315.	6.0	89
66	Validation and simplification of a score predicting survival in patients irradiated for metastatic spinal cord compression. <i>Cancer</i> , 2010, 116, 3670-3673.	4.1	85
67	Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. <i>European Urology</i> , 2018, 73, 427-435.	1.9	84
68	Patterns of care for brachytherapy in Europe: Updated results. <i>Radiotherapy and Oncology</i> , 2010, 97, 514-520.	0.6	81
69	An immunohistochemical assessment of hypoxia in prostate carcinoma using pimonidazole: Implications for radioresistance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 91-99.	0.8	80
70	A Score Predicting Posttreatment Ambulatory Status in Patients Irradiated for Metastatic Spinal Cord Compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 905-908.	0.8	80
71	Spinal reirradiation after short-course RT for metastatic spinal cord compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 872-875.	0.8	79
72	Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 417-424.	0.8	78

#	ARTICLE	IF	CITATIONS
73	Justification for inter-fraction correction of catheter movement in fractionated high dose-rate brachytherapy treatment of prostate cancer. <i>Radiotherapy and Oncology</i> , 2009, 93, 253-258.	0.6	78
74	Prognostic factors for functional outcome and survival after reirradiation for in-field recurrences of metastatic spinal cord compression. <i>Cancer</i> , 2008, 113, 1090-1096.	4.1	77
75	Health-Related Quality of Life in Locally Advanced Cervical Cancer Patients After Definitive Chemoradiation Therapy Including Image Guided Adaptive Brachytherapy: An Analysis From the EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 94, 1088-1098.	0.8	77
76	Single-dose high-dose-rate brachytherapy compared to two and three fractions for locally advanced prostate cancer. <i>Radiotherapy and Oncology</i> , 2017, 124, 56-60.	0.6	75
77	Sarcopenia in cancer: Risking more than muscle loss. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2020, 16, 50-57.	1.9	75
78	Phase III Intergroup Study of Fludarabine Phosphate Compared With Cyclophosphamide, Vincristine, and Prednisone Chemotherapy in Newly Diagnosed Patients With Stage III and IV Low-Grade Malignant Non-Hodgkin's Lymphoma. <i>Journal of Clinical Oncology</i> , 2006, 24, 1590-1596.	1.6	73
79	Tumor Antivascular Effects of Radiotherapy Combined with Combretastatin A4 Phosphate in Human Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 1375-1380.	0.8	73
80	Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials. <i>Lancet Oncology</i> , The, 2021, 22, 246-255.	10.7	73
81	Quantitative Assessment of Lung Cancer Perfusion Using MDCT: Does Measurement Reproducibility Improve with Greater Tumor Volume Coverage?. <i>American Journal of Roentgenology</i> , 2006, 187, 1079-1084.	2.2	72
82	A Phase II Study of High-Dose-Rate Afterloading Brachytherapy as Monotherapy for the Treatment of Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 441-446.	0.8	72
83	Single vs multiple fraction palliative radiation therapy for bone metastases: Cumulative meta-analysis. <i>Radiotherapy and Oncology</i> , 2019, 141, 56-61.	0.6	71
84	Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 322, 2084.	7.4	71
85	Guidelines for the first line management of classical Hodgkin lymphoma. <i>British Journal of Haematology</i> , 2014, 166, 34-49.	2.5	70
86	Bowel morbidity following radiochemotherapy and image-guided adaptive brachytherapy for cervical cancer: Physician- and patient reported outcome from the EMBRACE study. <i>Radiotherapy and Oncology</i> , 2018, 127, 431-439.	0.6	69
87	Phase Ib trial of radiotherapy in combination with combretastatin-A4-phosphate in patients with non-small-cell lung cancer, prostate adenocarcinoma, and squamous cell carcinoma of the head and neck. <i>Annals of Oncology</i> , 2012, 23, 231-237.	1.2	68
88	A restatement of the natural science evidence base concerning the health effects of low-level ionizing radiation. <i>Proceedings of the Royal Society B: Biological Sciences</i> , 2017, 284, 20171070.	2.6	68
89	Short-course radiotherapy is not optimal for spinal cord compression due to myeloma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1452-1457.	0.8	66
90	High-dose-rate brachytherapy alone given as two or one fraction to patients for locally advanced prostate cancer: Acute toxicity. <i>Radiotherapy and Oncology</i> , 2014, 110, 268-271.	0.6	66

#	ARTICLE	IF	CITATIONS
91	Improvement in human tumour oxygenation with carbogen of varying carbon dioxide concentrations. <i>Radiotherapy and Oncology</i> , 1999, 50, 167-171.	0.6	65
92	Stereotactic Body Radiotherapy for Spinal and Bone Metastases. <i>Clinical Oncology</i> , 2015, 27, 298-306.	1.4	63
93	Change in Patterns of Failure After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 895-902.	0.8	62
94	Prostate post-implant dosimetry: Interobserver variability in seed localisation, contouring and fusion. <i>Radiotherapy and Oncology</i> , 2012, 104, 192-198.	0.6	61
95	Randomised trial of external-beam radiotherapy alone or with high-dose-rate brachytherapy for prostate cancer: Mature 12-year results. <i>Radiotherapy and Oncology</i> , 2021, 154, 214-219.	0.6	59
96	Neoadjuvant Cisplatin Chemotherapy Before Chemoradiation: A Flawed Paradigm?. <i>Journal of Clinical Oncology</i> , 2007, 25, 5281-5286.	1.6	58
97	Effect of Epoetin Alfa on Survival and Cancer Treatment-Related Anemia and Fatigue in Patients Receiving Radical Radiotherapy With Curative Intent for Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 5751-5756.	1.6	58
98	Guidelines on the investigation and management of follicular lymphoma. <i>British Journal of Haematology</i> , 2012, 156, 446-467.	2.5	58
99	Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. <i>Prostate</i> , 2016, 76, 905-916.	2.3	58
100	Randomized Double-Blind Trial of Pregabalin Versus Placebo in Conjunction With Palliative Radiotherapy for Cancer-Induced Bone Pain. <i>Journal of Clinical Oncology</i> , 2016, 34, 550-556.	1.6	58
101	Prognostic factors predicting functional outcomes, recurrence-free survival, and overall survival after radiotherapy for metastatic spinal cord compression in breast cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 182-188.	0.8	57
102	Recommendations for the Use of Radiotherapy in Nodal Lymphoma. <i>Clinical Oncology</i> , 2013, 25, 49-58.	1.4	56
103	Overall survival benefit and safety profile of radium-223 chloride, a first-in-class alpha-pharmaceutical: Results from a phase III randomized trial (ALSYMPCA) in patients with castration-resistant prostate cancer (CRPC) with bone metastases. <i>Journal of Clinical Oncology</i> , 2012, 30, 8-8.	1.6	55
104	Antivascular Effects of Neoadjuvant Androgen Deprivation for Prostate Cancer: An In Vivo Human Study Using Susceptibility and Relaxivity Dynamic MRI. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 721-727.	0.8	54
105	Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial. <i>Radiotherapy and Oncology</i> , 2013, 108, 40-47.	0.6	54
106	Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. <i>Radiotherapy and Oncology</i> , 2018, 127, 423-430.	0.6	54
107	Organ at risk delineation for radiation therapy clinical trials: Global Harmonization Group consensus guidelines. <i>Radiotherapy and Oncology</i> , 2020, 150, 30-39.	0.6	53
108	Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens. <i>British Journal of Haematology</i> , 2005, 130, 363-372.	2.5	52

#	ARTICLE	IF	CITATIONS
109	4 Gy versus 24 Gy radiotherapy for follicular and marginal zone lymphoma (FoRT): long-term follow-up of a multicentre, randomised, phase 3, non-inferiority trial. <i>Lancet Oncology</i> , The, 2021, 22, 332-340.	10.7	51
110	Patientsâ€™ and health care professionalsâ€™ evaluation of health-related quality of life issues in bone metastases. <i>European Journal of Cancer</i> , 2009, 45, 2510-2518.	2.8	50
111	Targeted radio-nuclide therapy of skeletal metastases. <i>Cancer Treatment Reviews</i> , 2013, 39, 18-26.	7.7	50
112	Effect of 18F-Fluciclovine Positron Emission Tomography on the Management of Patients With Recurrence of Prostate Cancer: Results From the FALCON Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 316-324.	0.8	50
113	A role for radiotherapy in neuropathic bone pain: preliminary response rates from a prospective trial (Trans-Tasman Radiation Oncology Group, TROG 96.05). <i>International Journal of Radiation Oncology Biology Physics</i> , 2000, 46, 975-981.	0.8	49
114	Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis. <i>Annals of Palliative Medicine</i> , 2017, 6, 125-142.	1.2	49
115	Risk of Premature Menopause After Treatment for Hodgkinâ€™s Lymphoma. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	48
116	Re-irradiation for painful bone metastases â€“ A systematic review. <i>Radiotherapy and Oncology</i> , 2014, 110, 61-70.	0.6	48
117	Reproducibility and correlation between quantitative and semiquantitative dynamic and intrinsic susceptibility-weighted MRI parameters in the benign and malignant human prostate. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 32, 155-164.	3.4	47
118	Operable Nonâ€“Small Cell Lung Cancer: Correlation of Volumetric Helical Dynamic Contrast-enhanced CT Parameters with Immunohistochemical Markers of Tumor Hypoxia. <i>Radiology</i> , 2012, 264, 581-589.	7.3	47
119	High dose rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. <i>Radiotherapy and Oncology</i> , 2004, 73, 195-198.	0.6	43
120	Evaluation of Functional Outcome and Local Control After Radiotherapy for Metastatic Spinal Cord Compression in Patients With Prostate Cancer. <i>Journal of Urology</i> , 2006, 175, 552-556.	0.4	43
121	Carbogen and nicotinamide in locally advanced bladder cancer: Early results of a phase-III randomized trial. <i>Radiotherapy and Oncology</i> , 2009, 91, 120-125.	0.6	43
122	Applicator reconstruction for HDR cervix treatment planning using images from 0.35T open MR scanner. <i>Radiotherapy and Oncology</i> , 2010, 94, 346-352.	0.6	43
123	Validation of a Score Predicting Post-Treatment Ambulatory Status After Radiotherapy for Metastatic Spinal Cord Compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 79, 1503-1506.	0.8	42
124	Escalation of radiation dose beyond 30 Gy in 10 fractions for metastatic spinal cord compression. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 525-531.	0.8	41
125	Nodal failure after chemo-radiation and MRI guided brachytherapy in cervical cancer: Patterns of failure in the EMBRACE study cohort. <i>Radiotherapy and Oncology</i> , 2019, 134, 185-190.	0.6	41
126	Accelerated Radiotherapy, Carbogen, and Nicotinamide (ARCON) in the Treatment of Advanced Bladder Cancer: Mature Results of a Phase II Nonrandomized Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 1425-1431.	0.8	40



#	ARTICLE	IF	CITATIONS
127	Quality of Life in Men With Prostate Cancer Randomly Allocated to Receive Docetaxel or Abiraterone in the STAMPEDE Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 825-836.	1.6	40
128	Functional outcome and survival after radiotherapy of metastatic spinal cord compression in patients with cancer of unknown primary. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 532-537.	0.8	39
129	Second primary cancers after radiation for prostate cancer: a review of data from planning studies. <i>Radiation Oncology</i> , 2013, 8, 172.	2.7	39
130	Critical structure movement in cervix brachytherapy. <i>Radiotherapy and Oncology</i> , 2013, 107, 39-45.	0.6	39
131	A Delphi consensus study on salvage brachytherapy for prostate cancer relapse after radiotherapy, a Uro-GEC study. <i>Radiotherapy and Oncology</i> , 2016, 118, 122-130.	0.6	39
132	Risk Factors for Ureteral Stricture After Radiochemotherapy Including Image Guided Adaptive Brachytherapy in Cervical Cancer: Results From the EMBRACE Studies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 887-894.	0.8	39
133	Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma. , 1999, 86, 1322-1328.		38
134	FTIR microspectroscopy of selected rare diverse subvariants of carcinoma of the urinary bladder. <i>Journal of Biophotonics</i> , 2013, 6, 73-87.	2.3	38
135	Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: a systematic review and meta-analysis of randomized clinical trials. <i>Haematologica</i> , 2017, 102, 1748-1757.	3.5	38
136	Positron Emission Tomography Score Has Greater Prognostic Significance Than Pretreatment Risk Stratification in Early-Stage Hodgkin Lymphoma in the UK RAPID Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1732-1741.	1.6	38
137	Innovative Technologies in Radiation Therapy: Brachytherapy. <i>Seminars in Radiation Oncology</i> , 2006, 16, 209-217.	2.2	36
138	Carbogen and Nicotinamide Increase Blood Flow and 5-Fluorouracil Delivery but not 5-Fluorouracil Retention in Colorectal Cancer Metastases in Patients. <i>Clinical Cancer Research</i> , 2006, 12, 3115-3123.	7.0	35
139	Radiotherapy of metastatic spinal cord compression in very elderly patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 256-263.	0.8	35
140	Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial. <i>PLoS Medicine</i> , 2022, 19, e1003998.	8.4	35
141	Cervical brachytherapy utilizing ring applicator: Comparison of standard and conformal loading. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 63, 934-939.	0.8	34
142	High-dose-rate afterloading intraluminal brachytherapy for advanced inoperable rectal carcinoma. <i>Brachytherapy</i> , 2010, 9, 66-70.	0.5	34
143	ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases. <i>Radiotherapy and Oncology</i> , 2022, 173, 240-253.	0.6	34
144	Accelerated radiotherapy, carbogen and nicotinamide (ARCON) in locally advanced head and neck cancer: a feasibility study. <i>Radiotherapy and Oncology</i> , 1997, 45, 159-166.	0.6	33

#	ARTICLE	IF	CITATIONS
145	Overview of brachytherapy resources in Europe: A survey of patterns of care study for brachytherapy in Europe. <i>Radiotherapy and Oncology</i> , 2007, 82, 50-54.	0.6	33
146	Risk factors and dose-effects for bladder fistula, bleeding and cystitis after radiotherapy with imaged-guided adaptive brachytherapy for cervical cancer: An EMBRACE analysis. <i>Radiotherapy and Oncology</i> , 2021, 158, 312-320.	0.6	33
147	Long-Term Outcomes of Radical Radiation Therapy with Hypoxia Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 1407-1415.	0.8	33
148	Clinical applications of multiparametric MRI within the prostate cancer diagnostic pathway. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 281-284.	1.6	32
149	Impact of Reirradiation of Painful Osseous Metastases on Quality of Life and Function: A Secondary Analysis of the NCIC CTG SC.20 Randomized Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 3867-3873.	1.6	32
150	Squamous-cell carcinoma of the anus: progress in radiotherapy treatment. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 447-459.	27.6	32
151	Minimal clinically important differences in the EORTC QLQ-C30 and brief pain inventory in patients undergoing re-irradiation for painful bone metastases. <i>Quality of Life Research</i> , 2018, 27, 1089-1098.	3.1	32
152	Administration of nicotinamide during chart: Pharmacokinetics, dose escalation, and clinical toxicity. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995, 32, 1111-1119.	0.8	31
153	High dose rate brachytherapy for prostate cancer. <i>Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique</i> , 2008, 12, 512-514.	1.4	31
154	Organ preservation in bladder cancer: an opportunity for truly personalized treatment. <i>Nature Reviews Urology</i> , 2019, 16, 511-522.	3.8	31
155	Dose-Volume Effects and Risk Factors for Late Diarrhea in Cervix Cancer Patients After Radiochemotherapy With Image Guided Adaptive Brachytherapy in the EMBRACE I Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 688-700.	0.8	31
156	High-dose-rate brachytherapy with two or three fractions as monotherapy in the treatment of locally advanced prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 112, 63-67.	0.6	30
157	Fatigue, insomnia and hot flashes after definitive radiochemotherapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: An analysis from the EMBRACE study. <i>Radiotherapy and Oncology</i> , 2018, 127, 440-448.	0.6	30
158	Salvage stereotactic body radiotherapy (SBRT) for intraprostatic relapse after prostate cancer radiotherapy: An ESTRO ACROP Delphi consensus. <i>Cancer Treatment Reviews</i> , 2021, 98, 102206.	7.7	30
159	A Multicenter Randomized Trial of Ibandronate Compared With Single-Dose Radiotherapy for Localized Metastatic Bone Pain in Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv197.	6.3	29
160	ECCO Essential Requirements for Quality Cancer Care: Prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 148, 102861.	4.4	29
161	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	5.1	29
162	Efficacy of multiple fraction conventional radiation therapy for painful uncomplicated bone metastases: A systematic review. <i>Radiotherapy and Oncology</i> , 2017, 122, 323-331.	0.6	28

#	ARTICLE	IF	CITATIONS
163	GEC-ESTRO ACROP prostate brachytherapy guidelines. <i>Radiotherapy and Oncology</i> , 2022, 167, 244-251.	0.6	28
164	ESTRO ACROP guidelines for external beam radiotherapy of patients with uncomplicated bone metastases. <i>Radiotherapy and Oncology</i> , 2022, 173, 197-206.	0.6	28
165	High dose rate brachytherapy boost treatment in radical radiotherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2000, 57, 285-288.	0.6	27
166	A review of patterns of practice and clinical guidelines in the palliative radiation treatment of uncomplicated bone metastases. <i>Radiotherapy and Oncology</i> , 2017, 124, 38-44.	0.6	27
167	Acute and late morbidity in the treatment of advanced bladder carcinoma with accelerated radiotherapy, carbogen, and nicotinamide. <i>Cancer</i> , 2005, 103, 2287-2297.	4.1	26
168	External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 525-533.	0.8	26
169	Addition of Androgen-Deprivation Therapy or Brachytherapy Boost to External Beam Radiotherapy for Localized Prostate Cancer: A Network Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2020, 38, 3024-3031.	1.6	26
170	Nicotinamide Pharmacokinetics in Normal Volunteers and Patients Undergoing Palliative Radiotherapy. <i>Acta Oncol</i> , 1996, 35, 213-219.	1.8	25
171	Vaginal vault brachytherapy as sole postoperative treatment for low-risk endometrial cancer. <i>Brachytherapy</i> , 2008, 7, 195-199.	0.5	25
172	Hypoxia dose painting in prostate and cervix cancer. <i>Acta Oncol</i> , 2015, 54, 1259-1262.	1.8	25
173	A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol. <i>BMC Cancer</i> , 2020, 20, 198.	2.6	25
174	Colorectal cancer: summary of NICE guidance. <i>BMJ</i> , 2020, 368, m461.	6.0	25
175	Image-guided vulvovaginal interstitial brachytherapy in the treatment of primary and recurrent gynecological malignancies. <i>Brachytherapy</i> , 2012, 11, 306-310.	0.5	24
176	Loss of expression of the tumour suppressor gene <i>AIMP3</i> predicts survival following radiotherapy in muscle-invasive bladder cancer. <i>International Journal of Cancer</i> , 2015, 136, 709-720.	5.1	24
177	Clinical trials targeting hypoxia. <i>British Journal of Radiology</i> , 2019, 92, 20170966.	2.2	24
178	Nomogram Predicting Overall Survival in Patients With Locally Advanced Cervical Cancer Treated With Radiochemotherapy Including Image-Guided Brachytherapy: A Retro-EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 168-177.	0.8	24
179	Dosimetry and field matching for radiotherapy to the breast and supraclavicular fossa. <i>Radiotherapy and Oncology</i> , 2009, 91, 42-48.	0.6	23
180	Malignant epidural spinal cord compression. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 103-108.	1.3	23

#	ARTICLE	IF	CITATIONS
181	Physician assessed and patient reported lower limb edema after definitive radio(chemo)therapy and image-guided adaptive brachytherapy for locally advanced cervical cancer: A report from the EMBRACE study. <i>Radiotherapy and Oncology</i> , 2018, 127, 449-455.	0.6	23
182	MRE11 as a Predictive Biomarker of Outcome After Radiation Therapy in Bladder Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 809-818.	0.8	23
183	Importance of the ICRU bladder point dose on incidence and persistence of urinary frequency and incontinence in locally advanced cervical cancer: An EMBRACE analysis. <i>Radiotherapy and Oncology</i> , 2021, 158, 300-308.	0.6	23
184	Short-Course Radiotherapy (RT) for Metastatic Spinal Cord Compression (MSCC) Due to Renal Cell Carcinoma: Results of a Retrospective Multi-Center Study. <i>European Urology</i> , 2006, 49, 846-852.	1.9	22
185	Elevated lactate dehydrogenase levels detected during routine follow-up do not predict relapse in patients with diffuse large B-cell lymphoma who achieve complete remission after primary treatment with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone-like immunochemotherapy. <i>Leukemia and Lymphoma</i> , 2012, 53, 1949-1952.	1.3	22
186	IAEA randomised trial of optimal single dose radiotherapy in the treatment of painful bone metastases. <i>Radiotherapy and Oncology</i> , 2015, 116, 10-14.	0.6	22
187	Is Short-Course Radiotherapy with High Doses per Fraction the Appropriate Regimen for Metastatic Spinal Cord Compression in Colorectal Cancer Patients?. <i>Strahlentherapie Und Onkologie</i> , 2006, 182, 708-712.	2.0	21
188	The Influence of Prostate Volume on Outcome After High-Dose-Rate Brachytherapy Alone for Localized Prostate Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 270-274.	0.8	21
189	New approaches for effective and safe pelvic radiotherapy in high-risk prostate cancer. <i>Nature Reviews Urology</i> , 2019, 16, 523-538.	3.8	21
190	Lost in application: Measuring hypoxia for radiotherapy optimisation. <i>European Journal of Cancer</i> , 2021, 148, 260-276.	2.8	21
191	Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 3591-3601.	1.6	21
192	Defining the appropriate radiotherapy regimen for metastatic spinal cord compression in non-small cell lung cancer patients. <i>European Journal of Cancer</i> , 2006, 42, 1052-1056.	2.8	20
193	Results of the 2nd Planned Interim Analysis of the RAPID Trial (involved field radiotherapy versus no) Tj ETQq1 1 0.784314 rgBT /Overl FDG-PET Scan after 3 Cycles ABVD. <i>Blood</i> , 2008, 112, 369-369.	1.4	20
194	Single dose high-dose rate (HDR) brachytherapy (BT) as monotherapy for localised prostate cancer: Early results of a UK national cohort study. <i>Radiotherapy and Oncology</i> , 2020, 143, 95-100.	0.6	19
195	Protons and more: state of the art in radiotherapy. <i>Clinical Medicine</i> , 2014, 14, s61-s65.	1.9	18
196	Dosimetric predictors of biochemical control of prostate cancer in patients randomised to external beam radiotherapy with a boost of high dose rate brachytherapy. <i>Radiotherapy and Oncology</i> , 2014, 110, 110-113.	0.6	18
197	Radiation Dose in Spinal Cord Compression. <i>Journal of Clinical Oncology</i> , 2005, 23, 8270-8270.	1.6	17
198	Five-year outcomes after iodine-125 seed brachytherapy for low-risk prostate cancer at three cancer centres in the UK. <i>BJU International</i> , 2014, 113, 748-753.	2.5	17

#	ARTICLE	IF	CITATIONS
199	Single-Dose Focal Salvage High Dose Rate Brachytherapy for Locally Recurrent Prostate Cancer. <i>Clinical Oncology</i> , 2020, 32, 259-265.	1.4	17
200	Salvage Reirradiation Options for Locally Recurrent Prostate Cancer: A Systematic Review. <i>Frontiers in Oncology</i> , 2021, 11, 681448.	2.8	17
201	Impact of hypoxia on cervical cancer outcomes. <i>International Journal of Gynecological Cancer</i> , 2021, 31, 1459-1470.	2.5	17
202	Quantitative helical dynamic contrast enhanced computed tomography assessment of the spatial variation in whole tumour blood volume with radiotherapy in lung cancer. <i>Lung Cancer</i> , 2010, 69, 71-76.	2.0	16
203	Variations in Radiotherapy Delivery in England – Evidence from the National Radiotherapy Dataset. <i>Clinical Oncology</i> , 2013, 25, 531-537.	1.4	16
204	Overall response rates to radiation therapy for patients with painful uncomplicated bone metastases undergoing initial treatment and retreatment. <i>Radiotherapy and Oncology</i> , 2014, 112, 125-127.	0.6	16
205	Revisiting classification of pain from bone metastases as mild, moderate, or severe based on correlation with function and quality of life. <i>Supportive Care in Cancer</i> , 2016, 24, 1617-1623.	2.2	16
206	Persistence of Late Substantial Patient-Reported Symptoms (LAPERS) After Radiochemotherapy Including Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: A Report From the EMBRACE Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 161-173.	0.8	16
207	Ultra-hypofractionated radiotherapy for low- and intermediate risk prostate cancer: High-dose-rate brachytherapy vs stereotactic ablative radiotherapy. <i>Radiotherapy and Oncology</i> , 2021, 158, 184-190.	0.6	16
208	Final analysis of the UKLG LY02 trial comparing 6–8 cycles of CHOP with 3 cycles of CHOP followed by a BEAM autograft in patients <math>\leq 65</math> years with poor prognosis histologically aggressive NHL. <i>British Journal of Haematology</i> , 2010, 149, 237-243.	2.5	15
209	Clinical target volumes in anal cancer: Calculating what dose was likely to have been delivered in the UK ACT II trial protocol. <i>Radiotherapy and Oncology</i> , 2012, 103, 341-346.	0.6	15
210	Prospective multi-center dosimetry study of low-dose Iodine-125 prostate brachytherapy performed after transurethral resection. <i>Journal of Contemporary Brachytherapy</i> , 2013, 2, 63-69.	0.9	15
211	Dosimetric analysis of urethral strictures following HDR 192Ir brachytherapy as monotherapy for intermediate- and high-risk prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 410-413.	0.6	15
212	Use of bladder dose points for assessment of the spatial dose distribution in the posterior bladder wall in cervical cancer brachytherapy and the impact of applicator position. <i>Brachytherapy</i> , 2015, 14, 252-259.	0.5	15
213	Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 203-206.	5.2	15
214	I-125 seed planning: An alternative method of urethra definition. <i>Radiotherapy and Oncology</i> , 2010, 94, 24-29.	0.6	14
215	Optimal source distribution for focal boosts using high dose rate (HDR) brachytherapy alone in prostate cancer. <i>Radiotherapy and Oncology</i> , 2014, 113, 121-125.	0.6	14
216	Image Guided Brachytherapy in Cervical Cancer: A Comparison between Intracavitary and Combined Intracavitary/Interstitial Brachytherapy in Regard to Doses to HR CTV, OARs and Late Morbidity - Early Results from the Embrace Study in 999 Patients. <i>Brachytherapy</i> , 2016, 15, S21.	0.5	14

#	ARTICLE	IF	CITATIONS
217	Severity and Persistency of Late Gastrointestinal Morbidity in Locally Advanced Cervical Cancer: Lessons Learned From EMBRACE-I and Implications for the Future. International Journal of Radiation Oncology Biology Physics, 2022, 112, 681-693.	0.8	14
218	The effect of hypoxia on PD-L1 expression in bladder cancer. BMC Cancer, 2021, 21, 1271.	2.6	14
219	Quality assurance experience with the randomized neuropathic bone pain trial (Trans-Tasman) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.6	13
220	Improved Posttreatment Functional Outcome is Associated with Better Survival in Patients Irradiated for Metastatic Spinal Cord Compression. International Journal of Radiation Oncology Biology Physics, 2007, 67, 1506-1509.	0.8	13
221	Risk factors for nodal failure after radiochemotherapy and image guided brachytherapy in locally advanced cervical cancer: An EMBRACE analysis. Radiotherapy and Oncology, 2021, 163, 150-158.	0.6	12
222	Radiotherapy for metastatic bone disease: current standards and future prospectus. Expert Review of Anticancer Therapy, 2010, 10, 683-695.	2.4	11
223	Effect of re-irradiation for painful bone metastases on urinary markers of osteoclast activity (NCIC) Tj ETQq1 1 0.784314 rgBT /Overlock 1	0.6	11
224	Single-centre Experience of Use of Radium 223 with Clinical Outcomes Based on Number of Cycles and Bone Marrow Toxicity. Anticancer Research, 2018, 38, 5423-5427.	1.1	11
225	Opioids in context: relieving the pain of cancer. The role of comprehensive cancer management. Palliative Medicine, 2008, 22, 303-309.	3.1	10
226	Brachytherapy in the United Kingdom and Spain: a subset analysis of a European pattern of care survey. Clinical and Translational Oncology, 2009, 11, 534-538.	2.4	10
227	High dose rate brachytherapy for prostate cancer: Standard of care and future direction. Cancer Radiotherapy: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 66-72.	1.4	10
228	How should radiation oncologists interpret the ASTRO evidence-based guideline and ASTRO Choosing Wisely campaign for the treatment of uncomplicated bone metastases?. Practical Radiation Oncology, 2017, 7, 13-15.	2.1	10
229	Outcomes of radiosensitisation in elderly patients with advanced bladder cancer. Radiotherapy and Oncology, 2018, 129, 499-506.	0.6	10
230	Clinical Guidance for the Management of Patients with Urothelial Cancers During the COVID-19 Pandemic – Rapid Review. Clinical Oncology, 2020, 32, 347-353.	1.4	10
231	Developing Tumor Radiosensitivity Signatures Using LncRNAs. Radiation Research, 2021, 195, 324-333.	1.5	10
232	Developments in the management of Hodgkin's lymphoma. Lancet, The, 2010, 375, 786-788.	18.7	9
233	Predictive model for survival in patients having repeat radiation treatment for painful bone metastases. Radiotherapy and Oncology, 2016, 118, 547-551.	0.6	9
234	High dose simultaneous integrated boost for node positive cervical cancer. Radiation Oncology, 2021, 16, 92.	2.7	9

#	ARTICLE	IF	CITATIONS
235	Advances in radiotherapy in bone metastases in the context of new target therapies and ablative alternatives: A critical review. <i>Radiotherapy and Oncology</i> , 2021, 163, 55-67.	0.6	9
236	The optimism surrounding stereotactic body radiation therapy and immunomodulation. <i>Chinese Clinical Oncology</i> , 2017, 6, S9-S9.	1.2	9
237	Third Space Sequestration Increases Toxicity of Fludarabine:A Case Report. <i>Acta OncolÃ³gica</i> , 1997, 36, 441-441.	1.8	8
238	The modification of human tumour blood flow using pentoxifylline, nicotinamide and carbogen. <i>Radiotherapy and Oncology</i> , 2002, 62, 69-76.	0.6	8
239	Modelling second malignancy risks from low dose rate and high dose rate brachytherapy as monotherapy for localised prostate cancer. <i>Radiotherapy and Oncology</i> , 2016, 120, 293-299.	0.6	8
240	The costâ€effectiveness of immediate treatment or watch and wait with deferred chemotherapy for advanced asymptomatic follicular lymphoma. <i>British Journal of Haematology</i> , 2018, 180, 52-59.	2.5	8
241	A pilot study on dosimetric and radiomics analysis of urethral strictures following HDR brachytherapy as monotherapy for localized prostate cancer. <i>British Journal of Radiology</i> , 2020, 93, 20190760.	2.2	8
242	The role of palliative radiotherapy in bladder cancer: a narrative review. <i>Annals of Palliative Medicine</i> , 2020, 9, 4294-4299.	1.2	8
243	Hypoxic radiosensitizers in radical radiotherapy for patients with bladder carcinoma. <i>Cancer</i> , 1999, 86, 1322-1328.	4.1	8
244	Eligibility audits for the randomized neuropathic bone pain trial (TROG 96.05). <i>Journal of Medical Imaging and Radiation Oncology</i> , 2000, 44, 303-307.	0.6	7
245	The dosimetric impact of air in vaginal vault brachytherapy. <i>Brachytherapy</i> , 2016, 15, 832-838.	0.5	7
246	A history of transurethral resection of the prostate should not be a contra-indication for low-dose-rate 125I prostate brachytherapy: results of a prospective Uro-GEC phase-II trial. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 1-5.	0.9	7
247	Single dose high-dose-rate brachytherapy with focal dose escalation for prostate cancer: Mature results of a phase 2 clinical trial. <i>Radiotherapy and Oncology</i> , 2021, 159, 67-74.	0.6	7
248	Exclusive 3D-brachytherapy as a good option for stage-I inoperable endometrial cancer: a retrospective analysis in the gynaecological cancer GEC-ESTRO Working Group. <i>Clinical and Translational Oncology</i> , 2022, 24, 254-265.	2.4	7
249	Prognostic Implications of Uterine Cervical Cancer Regression During Chemoradiation Evaluated by the T-Score in the Multicenter EMBRACE I Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 379-389.	0.8	7
250	Recent important developments in the management of nonspine bone metastases. <i>Current Opinion in Supportive and Palliative Care</i> , 2012, 6, 80-84.	1.3	6
251	Hypoxia and angiogenic biomarkers in prostate cancer after external beam radiotherapy (EBRT) alone or combined with high-dose-rate brachytherapy boost (HDR-BTb). <i>Radiotherapy and Oncology</i> , 2019, 137, 38-44.	0.6	6
252	Comparison of radiographer interobserver image registration variability using cone beam CT and MR for cervix radiotherapy. <i>British Journal of Radiology</i> , 2020, 93, 20200169.	2.2	6

#	ARTICLE	IF	CITATIONS
253	Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study. <i>Radiotherapy and Oncology</i> , 2021, 157, 24-31.	0.6	6
254	A miRNA signature predicts benefit from addition of hypoxia-modifying therapy to radiation treatment in invasive bladder cancer. <i>British Journal of Cancer</i> , 2021, 125, 85-93.	6.4	6
255	Risk Factors for Late Persistent Fatigue After Chemoradiotherapy in Patients With Locally Advanced Cervical Cancer: An Analysis From the EMBRACE-I Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 1177-1189.	0.8	6
256	Bladder function after conservative surgery and high-dose rate brachytherapy for bladder prostate rhabdomyosarcoma. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29574.	1.5	6
257	Weekly chemotherapy using PMitCEBO in the palliation of recurrent non-Hodgkin's lymphoma. <i>Acta Oncologica</i> , 1997, 36, 573-576.	1.8	5
258	Bladder conservation for muscle-invasive bladder cancer. <i>Expert Review of Anticancer Therapy</i> , 2012, 12, 1015-1020.	2.4	5
259	Bladder cancer and the National Cancer Data Base: New insight or misinformation?. <i>Cancer</i> , 2018, 124, 1105-1107.	4.1	5
260	Single Fraction High-Dose-Rate Brachytherapy: Too Good to Be True?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 1054-1056.	0.8	5
261	Radical External-Beam Radiotherapy in Combination With Intracavitary Brachytherapy for Localized Carcinoma of the Cervix in Sri Lanka: Is Treatment Delayed Treatment Denied?. <i>JCO Global Oncology</i> , 2020, 6, 1574-1581.	1.8	5
262	Radioisotopes for metastatic bone pain. <i>Lancet Oncology</i> , The, 2005, 6, 353-354.	10.7	4
263	Recommendations for Radiotherapy Technique and Dose in Extra-nodal Lymphoma. <i>Clinical Oncology</i> , 2016, 28, 62-68.	1.4	4
264	Dosimetry of local failure with single dose 19 Gy high-dose-rate brachytherapy for prostate cancer. <i>Radiotherapy and Oncology</i> , 2021, 157, 93-98.	0.6	4
265	Brachytherapy for locally advanced cervical cancer: A survey of UK provision of care and support. <i>Radiotherapy and Oncology</i> , 2021, 159, 60-66.	0.6	4
266	International survey of the treatment of metastatic spinal cord compression. <i>Journal of Radiosurgery and SBRT</i> , 2015, 3, 237-245.	0.2	4
267	Non-surgical treatment of localised prostate cancer. <i>Surgical Oncology</i> , 2009, 18, 255-267.	1.6	3
268	Focal boost to residual gross tumor volume in brachytherapy for cervical cancer—A feasibility study. <i>Brachytherapy</i> , 2018, 17, 181-186.	0.5	3
269	Predictive Biomarkers for Muscle-invasive Bladder Cancer: The Search for the Holy Grail Continues. <i>European Urology</i> , 2019, 76, 69-70.	1.9	3
270	Bayesian methods in palliative care research: cancer-induced bone pain. <i>BMJ Supportive and Palliative Care</i> , 2022, 12, e5-e9.	1.6	3



#	ARTICLE	IF	CITATIONS
271	Pain Response After Stereotactic Body Radiation Therapy Versus Conventional Radiation Therapy in Patients With Bone Metastases—A Phase 2, Randomized Controlled Trial Within a Prospective Cohort. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 368-370.	0.8	3
272	Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial. <i>Radiotherapy and Oncology</i> , 2022, 173, 77-83.	0.6	3
273	Update on the systematic review/meta-analysis of uncomplicated bone metastases treated with external beam radiation. <i>Radiotherapy and Oncology</i> , 2022, 174, 109-110.	0.6	3
274	Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial. <i>Radiotherapy and Oncology</i> , 2018, 126, 541-546.	0.6	2
275	Treatment of classical Hodgkin lymphoma in young adults aged 18–30 years with a modified paediatric Hodgkin lymphoma protocol. Results of a multicentre phase II clinical trial (CRUK/08/012). <i>British Journal of Haematology</i> , 2020, 189, 128-132.	2.5	2
276	Radiobiologically derived biphasic fractionation schemes to overcome the effects of tumour hypoxia. <i>British Journal of Radiology</i> , 2020, 93, 20190250.	2.2	2
277	Risk factors for urethral stricture following external beam radiotherapy and HDR brachytherapy for prostate cancer. <i>Brachytherapy</i> , 2021, 20, 302-306.	0.5	2
278	Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. <i>Blood</i> , 2020, 136, 16-18.	1.4	2
279	A randomized trial of single versus multiple fractions (Fx) for re-irradiation (RE-RT) of painful bone metastases (PBM): NCIC CTG SC.20. <i>Journal of Clinical Oncology</i> , 2013, 31, 9502-9502.	1.6	2
280	Comparison of multiple gene expression platforms for measuring a bladder cancer hypoxia signature. <i>Molecular Medicine Reports</i> , 2022, 26, .	2.4	2
281	The Use of Angiogenic and Hypoxia Biomarkers to Predict the Benefit from Dose Escalation Using External Beam Radiotherapy Plus a High Dose-Rate Brachytherapy Boost Compared to External Beam Radiotherapy Alone in Localized Prostate Cancer. <i>Brachytherapy</i> , 2016, 15, S74-S75.	0.5	1
282	Can Hypofractionation and Immune Modulation Coexist?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 742-744.	0.8	1
283	Prostate: Low Dose Rate Brachytherapy. <i>Medical Radiology</i> , 2016, , 299-317.	0.1	1
284	Stanford V (SV) Regimen Versus ABVD for the Treatment of Advanced Hodgkin Lymphoma (HL): Results of a UK NCRI/LTO Randomised Phase II Trial. <i>Blood</i> , 2004, 104, 311-311.	1.4	1
285	Quality Control of PET Imaging in a Multicentre Phase III Trial (RAPID) Involving Randomisation of Patients with Stages IA and IIA Hodgkin Lymphoma Who Are PET negative™ after 3 Cycles of ABVD Chemotherapy. <i>Blood</i> , 2008, 112, 1449-1449.	1.4	1
286	Prostate Brachytherapy: High Dose Rate. , 2013, , 739-748.		1
287	Excess dose-related parameters (Vex, Rex, and iRex): novel predictors and late toxicity correlations in cervical cancer image-guided adaptive brachytherapy. <i>Journal of Contemporary Brachytherapy</i> , 2020, 12, 441-453.	0.9	1
288	Practical brachytherapy solutions to an age-old quandary. <i>Technical Innovations and Patient Support in Radiation Oncology</i> , 2020, 16, 39-47.	1.9	1

#	ARTICLE	IF	CITATIONS
289	Evaluation of the Patient with Bone Metastases at Presentation. , 2006, , 545-554.		0
290	Bone Metastases. Medical Radiology, 2010, , 191-208.	0.1	0
291	High dose rate brachytherapy for prostate cancer: Standard of care and future direction. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 81-82.	1.4	0
292	High dose rate brachytherapy for prostate cancer: Standard of care and future direction. Cancer Radiotherapie: Journal De La Societe Francaise De Radiotherapie Oncologique, 2016, 20, 77.	1.4	0
293	Bone Metastases. Medical Radiology, 2016, , 317-336.	0.1	0
294	Treat All Known Disease. International Journal of Radiation Oncology Biology Physics, 2017, 98, 494.	0.8	0
295	Double the Target Volumes. International Journal of Radiation Oncology Biology Physics, 2021, 109, 846.	0.8	0
296	Response to Yuce Sari et al.. Radiotherapy and Oncology, 2021, 158, 323-324.	0.6	0
297	Hypofractionation: less is more?. Oncotarget, 2021, 12, 1729-1733.	1.8	0
298	Vascular Disruptive Agents in Combination with Radiotherapy. , 2010, , 231-250.		0
299	Assessment and management of respiratory symptoms of malignant disease. , 2012, , 319-346.		0
300	HDR Versus LDR Seeds. , 2013, , 179-186.		0
301	Reirradiation. Cancer Metastasis - Biology and Treatment, 2014, , 341-349.	0.1	0
302	The impact of an educational tool in cervix image registration across three imaging modalities. British Journal of Radiology, 2022, 95, .	2.2	0